Wockhardt's ZAYNICH wins US FDA approval, first Indian-origin NCE to do so.
A novel antibiotic for resistant infections posted an 89% cure rate versus 68.4% for meropenem in a Phase 3 trial. The US market now opens for a molecule born in an Indian lab.
— 2 earlier stories on Wockhardt Ltd. →What's new
- US FDA approved ZAYNICH, the first New Chemical Entity fully developed by an Indian company.
- The drug demonstrated an 89.0% composite cure rate versus 68.4% for meropenem in a 530-patient trial.
- European Medicines Agency review is ongoing; Indian clearance came in May.
Why this matters
This breaks a generational barrier for Indian pharma. Wockhardt spent 15 years and billions in R&D to get here. The approval validates that long bet and gives the company a first-in-class asset in a US market where complicated UTIs cause over 600,000 hospitalizations annually.
What we're watching
- US commercial launch timeline and peak-sales projections for ZAYNICH.
- The outcome of the European Medicines Agency review.
- Pricing and access strategy in a hospital-dominated antibacterial market.
The full read
Wockhardt just did what no Indian pharma company has done before. It took a molecule it discovered, ran it through late-stage trials, and won US FDA approval. The drug is ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. In a 530-patient Phase 3 trial, it posted an 89.0% composite cure rate versus 68.4% for meropenem. The approval clears the way for a US launch into a market where complicated UTIs cause over 600,000 hospitalizations a year. For Wockhardt, this is a pipeline that now has a revenue-generating asset. It also de-risks the next steps: a European review is underway, and Indian clearance came in May. Fifteen years of R&D ends with a single approval letter.
Questions answered
- Why is this approval a milestone for the Indian pharma industry?
- ZAYNICH is the first New Chemical Entity fully developed and commercialized by an Indian company to win US FDA approval. Prior Indian successes were generics or biosimilars, not novel molecules discovered in-house.
- How did the drug perform in its key trial?
- In the Phase 3 ENHANCE-1 trial of 530 patients, ZAYNICH achieved an 89.0% composite cure rate for complicated UTIs, significantly higher than the 68.4% rate for meropenem.
- What market is Wockhardt entering?
- Complicated urinary tract infections account for over 600,000 hospitalizations annually in the US. The approval targets a high-need area of antimicrobial resistance, where existing drugs often fail.
- What comes next after the FDA approval?
- A marketing application for ZAYNICH is still under review with the European Medicines Agency. In the US, Wockhardt must now execute a commercial launch, which will be the next major test for the company.
Story so far
All notes on WOCKPHARMA →- 30 May 2026 · 8:19 PM IST Wockhardt's ZAYNICH wins US FDA approval, first Indian-origin NCE to do so.
- 2d ago Wockhardt wins Indian approval for novel antibiotic Zaynich
- 9d ago Wockhardt's credit quality just improved — but the market already knew